Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could predict MS Flare-Ups, study hopes

NCT ID NCT06551519

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to see how often high sNfL levels occur and whether this information leads to better treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

489 people

The number who actually took part.

Started

Oct 2024

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multiple sclerosis patients currently treated with a DMT category 1 prior to study start and receive sNfL measurements

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants eligible for inclusion in this study must meet all the following criteria: 1. Written informed consent must be obtained before participation in the study. 2. RMS patients aged 18 or older. 3. Treated in label with EU-approved DMTs for MS category 1 according to current guidelines (Hemmer et al 2023) for at least the last 3 months. 4. Presence of a sNfL test result from a commercially available test not older than 3 months. Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this study: 1. Patients being treated outside of the approved label of the respective DMT. 2. Simultaneous participation in any interventional study or simultaneous participation in another Novartis-sponsored non-interventional study with ofatumumab.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Novartis Investigative Site

    Albstadt, Baden-Wurttemberg, 72458, Germany

  • Novartis Investigative Site

    Hettingen, Baden-Wurttemberg, 72513, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, 68163, Germany

  • Novartis Investigative Site

    Schwetzingen, Baden-Wurttemberg, 68723, Germany

  • Novartis Investigative Site

    Bamberg, Bavaria, 96052, Germany

  • Novartis Investigative Site

    Neuburg A.d. Donau, Bavaria, 86633, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, 93059, Germany

  • Novartis Investigative Site

    Unterhaching, Bavaria, 82008, Germany

  • Novartis Investigative Site

    Untermeitingen, Bavaria, 86836, Germany

  • Novartis Investigative Site

    Weiden in Der Oberpfalz, Bavaria, 92637, Germany

  • Novartis Investigative Site

    Hamburg, Free and Hanseatic City of Hamburg, 22297, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 65929, Germany

  • Novartis Investigative Site

    Kassel, Hesse, 34121, Germany

  • Novartis Investigative Site

    Quakenbrück, Lower Saxony, 49610, Germany

  • Novartis Investigative Site

    Dortmund, North Rhine-Westphalia, 44135, Germany

  • Novartis Investigative Site

    Dortmund, North Rhine-Westphalia, 44287, Germany

  • Novartis Investigative Site

    Gelsenkirchen, North Rhine-Westphalia, 45894, Germany

  • Novartis Investigative Site

    Meerbusch, North Rhine-Westphalia, 40667, Germany

  • Novartis Investigative Site

    Siegen, North Rhine-Westphalia, 57072, Germany

  • Novartis Investigative Site

    Sundern Sauerland, North Rhine-Westphalia, 59846, Germany

  • Novartis Investigative Site

    Chemnitz, Saxony, 09117, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Görlitz, Saxony, 02828, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04299, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04315, Germany

  • Novartis Investigative Site

    Altenburg, Thuringia, 04600, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Mühlhausen, Thuringia, 99974, Germany

  • Novartis Investigative Site

    Aalen, 73433, Germany

  • Novartis Investigative Site

    Altenholz, 24161, Germany

  • Novartis Investigative Site

    Aschaffenburg, 63739, Germany

  • Novartis Investigative Site

    Augsburg, 86150, Germany

  • Novartis Investigative Site

    Backnang, 71522, Germany

  • Novartis Investigative Site

    Bad Krozingen, 79189, Germany

  • Novartis Investigative Site

    Bergneustadt, 51702, Germany

  • Novartis Investigative Site

    Berlin, 10437, Germany

  • Novartis Investigative Site

    Berlin, 12099, Germany

  • Novartis Investigative Site

    Berlin, 12163, Germany

  • Novartis Investigative Site

    Berlin, 14057, Germany

  • Novartis Investigative Site

    Berlin, 14169, Germany

  • Novartis Investigative Site

    Bielefeld, 33647, Germany

  • Novartis Investigative Site

    Bochum, 44787, Germany

  • Novartis Investigative Site

    Bogen, 94327, Germany

  • Novartis Investigative Site

    Bonn, 53111, Germany

  • Novartis Investigative Site

    Chemnitz, 09117, Germany

  • Novartis Investigative Site

    Coburg, 96450, Germany

  • Novartis Investigative Site

    Dessau, 06846, Germany

  • Novartis Investigative Site

    Dierdorf, 56269, Germany

  • Novartis Investigative Site

    Dillingen Saar, 66763, Germany

  • Novartis Investigative Site

    Dresden, 01067, Germany

  • Novartis Investigative Site

    Duisburg, 47138, Germany

  • Novartis Investigative Site

    Düsseldorf, 40211, Germany

  • Novartis Investigative Site

    Düsseldorf, 40625, Germany

  • Novartis Investigative Site

    Eisleben Lutherstadt, 06295, Germany

  • Novartis Investigative Site

    Erbach im Odenwald, 64711, Germany

  • Novartis Investigative Site

    Erfurt, 99096, Germany

  • Novartis Investigative Site

    Essen, 45138, Germany

  • Novartis Investigative Site

    Gelsenkirchen, 45879, Germany

  • Novartis Investigative Site

    Gera, 07548, Germany

  • Novartis Investigative Site

    Hagen, 58099, Germany

  • Novartis Investigative Site

    Hamburg, 22179, Germany

  • Novartis Investigative Site

    Heidenheim, 89518, Germany

  • Novartis Investigative Site

    Herford, 32049, Germany

  • Novartis Investigative Site

    Höxter, 37671, Germany

  • Novartis Investigative Site

    Itzehoe, 25524, Germany

  • Novartis Investigative Site

    Karlsruhe, 76133, Germany

  • Novartis Investigative Site

    Katzenelnbogen, 56368, Germany

  • Novartis Investigative Site

    Leipzig, 04109, Germany

  • Novartis Investigative Site

    Merzig, 66663, Germany

  • Novartis Investigative Site

    Minden, 32423, Germany

  • Novartis Investigative Site

    München, 80939, Germany

  • Novartis Investigative Site

    München, 81675, Germany

  • Novartis Investigative Site

    Münster, 48149, Germany

  • Novartis Investigative Site

    Neuwied, 56564, Germany

  • Novartis Investigative Site

    Osnabrück, 49074, Germany

  • Novartis Investigative Site

    Pforzheim, 75172, Germany

  • Novartis Investigative Site

    Remscheid, 42853, Germany

  • Novartis Investigative Site

    Rülzheim, 76761, Germany

  • Novartis Investigative Site

    Salzatal, 06198, Germany

  • Novartis Investigative Site

    Schwäbisch Hall, 74523, Germany

  • Novartis Investigative Site

    Siegen, 57076, Germany

  • Novartis Investigative Site

    Singen, 78224, Germany

  • Novartis Investigative Site

    Sinsheim, 74889, Germany

  • Novartis Investigative Site

    Stuttgart, 70174, Germany

  • Novartis Investigative Site

    Tirschenreuth, 95643, Germany

  • Novartis Investigative Site

    Ulm, 89073, Germany

  • Novartis Investigative Site

    Velbert, 42551, Germany

  • Novartis Investigative Site

    Weil der Stadt, 71263, Germany

  • Novartis Investigative Site

    Wolfenbüttel, 38300, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.